This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novavax (NVAX) Q2 Earnings Miss, Cuts '22 Sales Guidance by Half
by Zacks Equity Research
Novavax (NVAX) reports dismal results in second-quarter 2022. The stock dives in after-market trading after management slashes revenue guidance for 2022 by half.
Reata (RETA) Q2 Earnings Miss, Revenues Down Y/Y, Stock Down
by Zacks Equity Research
Reata (RETA) reports a wider-than-expected loss in the second quarter of 2022, while revenues miss estimates. Stock falls after updates on pipeline programs.
Apellis (APLS) Q2 Earnings and Sales Miss Estimates, Stock Down
by Zacks Equity Research
Apellis' (APLS) missed earnings and sales estimates in the second quarter of 2022. Consequently, the stock declines.
Novavax (NVAX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -218.51% and 82.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts. CLVS faces the risk of a cash crunch.
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
by Zacks Equity Research
Puma Biotech (PBYI) beats earnings and revenue estimates in second-quarter 2022. PBYI's stock surges at market close following the news.
Biohaven Pharmaceutical (BHVN) Q2 Earnings Lag, Sales Beat
by Zacks Equity Research
Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. BHVN also reports a wider-than-expected Q2 loss.
Agios (AGIO) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Agios Pharmaceuticals' (AGIO) posts encouraging results for the second quarter. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.
Nektar's (NKTR) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Nektar (NKTR) reports dismal second-quarter 2022 results. The company's operating expenses increased due to restructuring expenses of $106.0 million incurred during the quarter.
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $61.93, moving +1.34% from the previous trading session.
Eli Lilly (LLY) Misses on Q1 Earnings, Lowers Earnings Guidance
by Zacks Equity Research
Eli Lilly's (LLY) earnings and sales miss second-quarter estimates. The company lowers its earnings outlook for 2022. The stock falls in pre-market trading.
Jazz's (JAZZ) Q2 Earnings Beat, New Drugs Post Robust Sales
by Zacks Equity Research
JAZZ's Q2 earnings and sales beat expectations on strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. The company affirms its 2022 guidance.
Mirati (MRTX) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Mirati Therapeutics' (MRTX) Q2 earnings and sales beat the mark. The company plans to start early-stage clinical studies for a SOS1 inhibitor by year-end.
Esperion (ESPR) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports dismal second-quarter results, missing estimates for earnings and sales. However, shares rose on the back of ESPR's progress with its cardiovascular outcome study.
Sanofi (SNY) Q2 Earnings & Sales Beat, Ups 2022 Growth View
by Zacks Equity Research
Sanofi (SNY) beats second-quarter estimates for earnings and sales. Dupixent drives sales growth and a strong recovery in travel vaccines. The company raises its earnings growth guidance for 2022.
Novavax (NVAX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) second-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $56.41, marking a -0.25% move from the previous day.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $58.95, moving -1.04% from the previous trading session.
Biotech Stock Roundup: APLS, NVAX Gain on Updates, INCYs Regulatory News & More
by Zacks Equity Research
'Regulatory and other updates from Apellis (APLS) and Novavax (NAVX) are a few key highlights from the biotech sector during the past week.
Novavax (NVAX) Up as CDC Endorses COVID Jab for Use in Adults
by Zacks Equity Research
Following the endorsement by the U.S. CDC, Novavax (NVAX) can now start immunizations with its COVID-19 vaccine as a primary two-dose regimen for use in adults in the United States.
Novavax (NVAX) Soars 5.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Novavax (NVAX) Down as EU Adds Side Effects to COVID Jab Label
by Zacks Equity Research
The administration of Novavax's (NVAX) COVID-19 vaccine leads to some cases of severe allergic reactions as well as skin problems, per a safety update issued by the EMA.
Biotech Stock Roundup: ICPT's Study Data, NVAX Vaccine Gets EUA, VERU Up on Data
by Zacks Equity Research
Regulatory and other updates from Intercept (ICPT) and VERU are a few key highlights from the biotech sector during the past week.
Novavax's (NVAX) Protein-Based COVID Jab Gets EUA in the US
by Zacks Equity Research
Following the grant of emergency use authorization by the FDA, Novavax's (NVAX) COVID-19 vaccine is the first protein-based COVID vaccine authorized for use in the United States.
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $69.95 in the latest trading session, marking a +0.27% move from the prior day.